arabinofuranosylcytosine triphosphate has been researched along with Disease Models, Animal in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Axelsson, H; Bladh, J; Bulli, L; Calderón-Montaño, JM; Grandér, D; Hagenkort, A; Helleday, T; Henter, JI; Herold, N; Heshmati, Y; Heyman, M; Höglund, A; Jemth, AS; Kogner, P; Kutzner, J; Lehmann, S; Ljungblad, L; Loseva, O; Lundbäck, T; Myrberg, IH; Page, BD; Paulin, CB; Rassidakis, G; Rudd, SG; Sanjiv, K; Schaller, T; Sundin, M; Tamm, KP; Tesi, B; Uhlin, M; Valerie, NC; Walfridsson, J; Warpman-Berglund, U; Wiita, E | 1 |
1 other study(ies) available for arabinofuranosylcytosine triphosphate and Disease Models, Animal
| Article | Year |
|---|---|
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinofuranosylcytosine Triphosphate; Child; Child, Preschool; Cytarabine; Disease Models, Animal; Female; Humans; In Vitro Techniques; Infant; Leukemia, Myeloid, Acute; Male; Mice; Molecular Targeted Therapy; Monomeric GTP-Binding Proteins; Prognosis; SAM Domain and HD Domain-Containing Protein 1; Viral Regulatory and Accessory Proteins | 2017 |